Dr. Konduri Discusses Promise of NGS Testing in NSCLC

Kartik Konduri, MD
Published: Tuesday, Apr 30, 2019



Kartik Konduri, MD, medical director, Chest Cancer Research and Treatment Center, Baylor Charles A. Sammons Cancer Center, Baylor Scott & White Health, discusses the promise of next-generation sequencing (NGS) in patients with non–small cell lung cancer (NSCLC).

Because HER2, MET, and NTRK are quite rare in NSCLC, it can be a challenge for physicians to detect these alterations. NGS has emerged as the preferred method of genetic testing in many academic centers because they enable physicians to detect these alterations with one test, Konduri says. When physicians find these genetic abnormalities in patients, they can potentially pair the patient with an effective targeted therapy.

Over the next few years, Konduri predicts that the technology behind NGS will improve. It will become a simple test for physicians to use in the future. However, that doesn’t eliminate the challenge of gathering sufficient tissue samples from patients, notes Konduri. As such, liquid biopsies will have to be further refined in the absence of sufficient tissue samples.
SELECTED
LANGUAGE


Kartik Konduri, MD, medical director, Chest Cancer Research and Treatment Center, Baylor Charles A. Sammons Cancer Center, Baylor Scott & White Health, discusses the promise of next-generation sequencing (NGS) in patients with non–small cell lung cancer (NSCLC).

Because HER2, MET, and NTRK are quite rare in NSCLC, it can be a challenge for physicians to detect these alterations. NGS has emerged as the preferred method of genetic testing in many academic centers because they enable physicians to detect these alterations with one test, Konduri says. When physicians find these genetic abnormalities in patients, they can potentially pair the patient with an effective targeted therapy.

Over the next few years, Konduri predicts that the technology behind NGS will improve. It will become a simple test for physicians to use in the future. However, that doesn’t eliminate the challenge of gathering sufficient tissue samples from patients, notes Konduri. As such, liquid biopsies will have to be further refined in the absence of sufficient tissue samples.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x